8I7 Stock Overview
A biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Gemina Laboratories Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.32 |
| 52 Week High | CA$0.40 |
| 52 Week Low | CA$0.22 |
| Beta | 0.27 |
| 1 Month Change | 1.26% |
| 3 Month Change | -1.23% |
| 1 Year Change | -12.97% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 6.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8I7 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.6% | 0.2% | 1.6% |
| 1Y | -13.0% | -24.4% | 7.3% |
Return vs Industry: 8I7 exceeded the German Biotechs industry which returned -24.9% over the past year.
Return vs Market: 8I7 underperformed the German Market which returned 6.5% over the past year.
Price Volatility
| 8I7 volatility | |
|---|---|
| 8I7 Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8I7 has not had significant price volatility in the past 3 months.
Volatility Over Time: 8I7's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 6 | Brian Firth | www.geminalabs.com |
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops Legio X, a COVID-19 rapid antigen test that validating the Gemina Surface Chemistry on this platform; and LEGIO X, an influenza AB multiplex lateral flow test. It is also developing a pipeline of products for the diagnosis of infectious respiratory diseases.
Gemina Laboratories Ltd. Fundamentals Summary
| 8I7 fundamental statistics | |
|---|---|
| Market cap | €24.91m |
| Earnings (TTM) | -€4.33m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.1x
P/E RatioIs 8I7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8I7 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$6.41m |
| Earnings | -CA$6.41m |
Last Reported Earnings
Oct 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.087 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -29.8% |
How did 8I7 perform over the long term?
See historical performance and comparison